Introduction
============

The vast genetic heterogeneity is not only characteristic of acute myeloid leukemia (AML) [@B1] but also has important prognostic implications. For example, *NPM1* mutation without positive *FLT3-ITD* is a good prognostic factor in cytogenetically normal AML (CN-AML) [@B2],[@B3], while the latter is a poor prognostic factor [@B4]. *DNMT3A* and *TP53* mutations are both negative prognostic factors in AML [@B5],[@B6]. Double *CEBPA* mutation is associated with favorable prognosis in CN-AML patients [@B7].

MicroRNAs (miRNAs) are short noncoding RNAs that regulate genes post-transcriptionally and play an important role in various physiological and developmental processes such as cell proliferation and differentiation, development, and apoptosis, all of which are frequently affected in cancer [@B8],[@B9]. Growing number of studies are demonstrating that the dysregulation of miRNAs is associated with the development and progression of many cancers including leukemia, and may provide useful prognostic information [@B10]-[@B13]. For instance, higher levels of miR-155 and lower levels of miR-181a are independently associated with shorter survival in CN-AML patients [@B14]. MiR-29a and miR-29b can induce apoptosis in AML by targeting apoptosis gene MCL-1 [@B15]. MiR-9 and miR-196b play essential oncogenic roles in mixed lineage leukemia-rearranged AML [@B16]. High miR-99a expression and low miR-215 expression are associated with worse clinical outcome in AML [@B17],[@B18].

MiR-98 belongs to the let-7 families that have been shown to be down-regulated in high-risk ovarian cancer, lung cancer, melanoma and other solid tumors [@B19]-[@B22]. Previous study found that let-7b and let-7c were tumor suppressors and would be down-regulated in AML with t(8;21) or inv(16) [@B23]. Here, we retrospectively studied the association between miR-98 expression and survival in AML patients to help elucidating its clinical and prognostic implications.

Materials and Methods
=====================

Patients
--------

A total of 164 AML patients with miR-98 expression data were identified in The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>) and enrolled in this study [@B24]. Ninety patients were treated with chemotherapy alone, and other 74 also received allogeneic hematopoietic stem cell transplant (allo-HSCT). All clinical and molecular information including miR-98 expression levels were publicly accessible from the TCGA website. All patients provided written informed consent; the research was approved by the Human Research Ethics Committee of Washington University. Primary endpoints were event-free survival (EFS) and overall survival (OS). EFS was defined as the time from diagnosis to removal from the study due to the absence of complete remission, relapse or death or was censored at the last follow-up. OS was defined as the time from diagnosis to death or was censored at the last follow-up.

Statistical Analysis
--------------------

All statistical analyses were performed by SPSS software 20.0 and GraphPad Prism software 5.0. The clinical and molecular characteristics of patients were summarized using descriptive statistics. The Mann-Whitney *U* test and the chi-square test were used to compare continuous and categorical data between the two groups, respectively. The EFS and OS rates were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazard models were constructed for uni- and multivariate analyses to identify the association between each clinical and molecular variable and survival. For all statistical analyses, *P* values were two-sided and *P* \< 0.05 was considered significant.

Results
=======

Associations between miR-98 expression and clinical and molecular characteristics of patients
---------------------------------------------------------------------------------------------

Patients were divided into two groups based on the treatment they received chemotherapy group and allo-HSCT group. Each group was then divided into two groups by the median expression level of miR-98. The clinical and molecular characteristics of each group were detailed in Table [1](#T1){ref-type="table"}.

In the chemotherapy group, high miR-98 expressers had lower percentages of bone marrow (BM) blasts (*P* = 0.048), more good-risk patients (*P* = 0.002) and fewer intermediate-risk patients (*P* = 0.011) than low expressers. Six patients among the high expressers harbored*RUNX1-RUNX1T*, whereas it was not found in low expressers (*P* = 0.026). High expressers had less in *NPM1* (*P* = 0.001) and *DNMT3A* (*P* = 0.002) mutations. No significant differences were found in age, gender distribution, WBC counts, peripheral blood (PB) blasts, French-American-British (FAB) classification, frequency of other recurrent genetic mutations (*FLT3-ITD*, *CEBPA*, *IDH1*/*IDH2*, *RUNX1*, *MLL-PTD*, *TP53*, *NRAS*/*KRAS* and *TET2*) and relapse rate between high and low miR-98 expression groups.

In the allo-HSCT group, high miR-98 expressers had younger (*P* = 0.043), more poor-risk (*P* = 0.047), and fewer intermediate-risk patients (*P* = 0.002) than low expressers. High expressers had less *NPM1* (*P* \< 0.001) and *DNMT3A* mutations (*P* = 0.007). No significant differences were found in gender distribution, BM blasts, FAB classification, karyotypes, frequency of other recurrent genetic mutations (*FLT3-ITD*, *CEBPA*,*IDH1*/*IDH2*, *RUNX1*, *MLL-PTD*, *NRAS*/*KRAS*, *TET2* and*TP53*) and relapse rate between high and low miR-98 expression groups.

Survival analysis of chemotherapy and allo-HSCT groups
------------------------------------------------------

Survival analyses were estimated using the Kaplan-Meier method. In chemotherapy group, high miR-98 expressers had a longer EFS (*P* = 0.003) and OS (*P* = 0.004; Figure [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B) compared with low expressers, but EFS and OS were not significantly different between high miR-98 expression group and low expression group in allo-HSCT group (Figure [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}D).

Prognostic value of miR-98 expression
-------------------------------------

To assess the prognostic significance of clinical and molecular characteristics, we chose miR-98 expression levels (low vs. high), age (\< 60 vs. ≥ 60 years), WBC counts (\< 20×10^9^/L vs. ≥ 20×10^9^/L), *FLT3-ITD* (positive vs. negative) and *NPM1* (mutated vs. wild),*DNMT3A* (mutated vs. wild) to do survival analysis.

In the chemotherapy group, univariate analysis indicated that low miR-98 expression and age ≥ 60 years were unfavorable for both EFS and OS (all *P* \< 0.01). Multivariate analysis showed that low miR-98 expression and age ≥ 60 years were independent risk factors for both EFS and OS (all *P* \< 0.05). WBC counts and other genetic abnormalities (*FLT3-ITD*, *NPM1*, *DNMT3A*) had no significant effect on EFS and OS (Table [2](#T2){ref-type="table"}).

In the allo-HSCT group, univariate and multivariate analyses all indicated that miR-98 had no association with EFS and OS. Other clinical and molecular parameters also had no impact on EFS and OS in this group (Table [3](#T3){ref-type="table"}).

In all patients, multivariate analysis indicated that allo-HSCT and age \< 60 years were independent favorable factors for both EFS and OS (all *P* \< 0.05) (Table [4](#T4){ref-type="table"}).

We also divided all patients into two groups based on median expression level of miR-98. In the low miR-98 expressers, allo-HSCT treatment were associated with longer EFS and OS than chemotherapy-alone (*P* = 0.001, *P* \< 0.001, respectively; Figure [2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}B), but EFS and OS were not significantly different in high miR-98 expressers (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D).

Associations between genome-wide miRNA and gene-expression profiles and miR-98 expression
-----------------------------------------------------------------------------------------

To further assess the role of miR-98 in AML, we derived miR-98-associated miRNA and gene expression profiles by high throughput sequencing from TCGA data. First, we found 251 up-regulated and 26 down-regulated miRNAs that were significantly associated with miR-98 expression (*P* \< 0.05, fold change = 1.5, Figure [3](#F3){ref-type="fig"}A). Second, we identified 277 genes were positively correlated with miR-98 expression, and 256 genes were negatively correlated with miR-98 expression (*P* \< 0.05, fold change = 1.5, Figure [3](#F3){ref-type="fig"}B). These genes were presented in the aberrant expression heat map (Figure [3](#F3){ref-type="fig"}C). Further gene ontology (GO) enrichment analysis indicated that the genes associated with miR-98 expression were mainly involved in \"embryonic skeletal system morphogenesis\", \"definitive hemopoiesis\", \"thyroid gland development\", \"negative regulation of myeloid cell differentiation\", \"L1CAM interactions\", \"signaling pathways regulating pluripotency of stem cells\", \"drug catabolic process\", \"sensory perception of sound\", and \"response to inorganic substance\" pathways. (Figure [3](#F3){ref-type="fig"}D).

Discussion
==========

Our study found that high miR-98 expression was more likely to occur in younger and good-risk patients, and more *RUNX1-RUNX1T* fusion was seen in high miR-98 expression group, suggesting that high miR-98 expression tend to coincide with good-risk AML and may have similar prognostic value as *RUNX1-RUNX1T*.

In the chemotherapy group, multivariate analysis had proved that low miR-98 expression and age ≥ 60 were independent adverse factors. But in the allo-HSCT group, univariate and multivariate analysis all showed no effect of miR-98 expression on EFS and OS, and in the entire cohort, the low miR-98 expressors who underwent allo-HSCT had longer EFS and OS. In all patients, multivariate analysis indicated that allo-HSCT was independent favorable factor for both EFS and OS. Thus, we speculated that the unfavorable influence of low miR-98 expression might be overcome by allo-HSCT.

The mechanisms of miR-98 in anti-tumorigenesis have been investigated. MiR-98 could suppress breast cancer angiogenesis and invasion by repressing the expression of *ALK4* and *MMP11* [@B25]. MiR-98 could also suppress the growth and metastasis of salivary adenoid cystic carcinomas by inhibiting the oncogene *NRAS* via the regulation of the *RAS/MAPK/ERK* and *PI3K/AKT* pathways [@B26] and suppress cell invasion and migration in glioma by directly targeting Pre-B Cell Leukemia Homeobox 3 [@B27]. It targeted *SALL4* to inhibit proliferation, migration, and invasion of hepatocellular carcinoma [@B28]. It inhibited melanoma metastasis via inhibiting IL-6 signaling pathway [@B22]. Mir-98 could negative regulate the expression of tumor suppressor gene FUS1b in lung cancers [@B29]. In leukemia, it was found that miR-98 upregulation could improve chemotherapy-sensitivity and decrease leukemia cell proliferation by inhibiting *E2F1* expression [@B30]. In the present study, miR-98 is associated with \"definitive hemopoiesis\", \"negative regulation of myeloid cell differentiation\", \"signaling pathways regulating pluripotency of stem cells\", and they play an important role in hematopoiesis, which suggests that miR-98 may play a prognostic role in leukemia by interacting with genes involved in these functional pathways. The detailed mechanism of miR-98 in AML leukemogenesis, however, should require further study.

In summary, we found that high miR-98 expression was a good prognostic factor in AML patients who only received chemotherapy. Patients with low miR-98 expression may benefit from allo-HSCT.
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![**Kaplan-Meier curves of EFS and OS in chemotherapy group and allo-HSCT group.** (A, B) In chemotherapy group, high miR-98 expressers had longer EFS and OS than low expressers. (C, D) EFS and OS were not significantly different between high miR-98 expression group and low expression group in allo-HSCT group.](jcav10p0178g001){#F1}

![**Kaplan-Meier curves of EFS and OS in high and low miR-98 expression groups.** (A, B) In low expression group, patients treated with allo-HSCT had longer EFS and OS than those treated with chemotherapy-only. (C, D) No significant survival differences were found between chemotherapy group and allo-HSCT group in high miR-98 expressors.](jcav10p0178g002){#F2}

![**Genome-wide gene/microRNA expression profile and cell signaling pathways associated with miR-98 expression.** (A) Volcano plot of differential microRNA expression. miR-98^high^ and miR-98^low^ were marked by red and green circles, respectively. (B) Volcano plot of differential gene expression. miR-98^high^ and miR-98^low^ were marked by red and green circles, respectively. (C) Expression heatmap of associated with miR-98 expression. (D) Gene ontology (GO) enrichment analysis of genes related to miR-98 expression.](jcav10p0178g003){#F3}

###### 

Clinical and molecular characteristics of patients in different treatment groups

  Characteristics                Chemotherapy group   Allo-HSCT group                                                               
  ------------------------------ -------------------- ----------------- ----------- ----------------- ----------------- ----------- --
  Age/years, median (range)      66 (22-88)           67 (31-83)        0.781^\*^   45 (18-72)        56 (21-69)        0.043^\*^   
  **Age group/n (%)**                                                   0.822^§^                                        0.116^§^    
  \< 60 years                    14 (31.1)            15 (33.3)                     30 (81.1)         24 (64.9)                     
  ≥ 60 years                     31 (68.9)            30 (66.7)                     7 (18.9)          13 (35.1)                     
  **Gender/n (%)**                                                      0.396^§^                                        0.159^§^    
  Male                           27 (60.0)            23 (51.1)                     24 (64.9)         18 (48.6)                     
  Female                         18 (40.0)            22 (48.9)                     13 (35.1)         19 (51.4)                     
  WBC/×10^9^/L, median (range)   14 (1.0-131.5)       36 (0.7-298.4)    0.062^\*^   29.4(1.2-223.8)   29.4(0.6-202.7)   0.510^\*^   
  BM blast/%, median (range)     69 (30-91)           76 (32-99)        0.048^\*^   71 (30-99)        75 (35-100)       0.210^\*^   
  PB blast/%, median (range)     25 (0-97)            46 (0-98)         0.508^\*^   48.5 (0-94)       45 (0-96)         0.699^\*^   
  **FAB subtypes/n (%)**                                                                                                            
  M0                             2 (4.4)              6 (13.3)          0.266^§^    3 (8.1)           6 (16.2)          0.479^§^    
  M1                             11 (24.4)            9 (20.0)          0.612^§^    11 (29.7)         12 (32.4)         0.802^§^    
  M2                             14 (31.1)            7 (15.6)          0.081^§^    10 (27.0)         9 (24.3)          0.790^§^    
  M3                             0 (0.0)              0 (0.0)                       1 (2.7)           1 (2.7)           1.000^§^    
  M4                             12 (26.7)            12 (26.7)         1.000^§^    9 (24.3)          5 (13.5)          0.235^§^    
  M5                             5 (11.1)             8 (17.6)          0.368^§^    1 (2.7)           3 (8.1)           0.615^§^    
  M6                             1 (2.2)              1 (2.2)           1.000^§^    1 (2.7)           0 (0.0)           1.000^§^    
  M7                             0 (0.0)              2 (4.4)           0.494^§^    1 (2.7)           1 (2.7)           1.000^§^    
  **Karyotype/n (%)**                                                                                                               
  Normal                         18 (40.0)            26 (57.8)         0.092^§^    11 (29.7)         23 (62.2)         0.005^§^    
  Complex                        7 (15.6)             5 (11.1)          0.535^§^    7 (18.9)          5 (13.5)          0.528^§^    
  8 Trisomy                      0 (0.0)              0 (0.0)                       3 (8.1)           3 (8.1)           1.000^§^    
  inv(16)/CBFβ-MYH11             6 (13.3)             1 (2.2)           0.110^§^    5 (13.5)          0 (0.0)           0.054^§^    
  11q23/MLL                      3 (6.7)              0 (0.0)                       2 (5.4)           1 (2.7)           1.000^§^    
  -7/7q-                         0 (0.0)              3 (6.7)           0.242^§^    2 (5.4)           1 (2.7)           1.000^§^    
  t(15;17)/PML-RARA              0 (0.0)              0 (0.0)                       1 (2.7)           1 (2.7)           1.000^§^    
  t(9;22)/BCR-ABL1               1 (2.2)              0 (0.0)           1.000^§^    2 (5.4)           0 (0.0)           0.493^§^    
  t(8;21)/RUNX1-RUNX1T1          6 (13.3)             0 (0.0)           0.026^§^    0 (0.0)           1 (2.7)           1.000^§^    
  Others                         4 (8.9)              10 (22.2)         0.144^§^    4 (10.8)          2 (5.4)           0.674^§^    
  **Risk/n (%)**                                                                                                                    
  Good                           12 (26.7)            1 (2.3)           0.002^§^    6 (16.7)          2 (5.4)           0.261^§^    
  Intermediate                   19 (42.2)            31 (72.1)         0.011^§^    14 (38.9)         27 (73.0)         0.002^§^    
  Poor                           14 (31.1)            11 (25.6)         0.480^§^    16 (44.4)         8 (21.6)          0.047^§^    
  ***FLT3-ITD*/n (%)**                                                  0.270^§^                                        0.782^§^    
  Positive                       6 (13.3)             10 (22.2)                     8 (21.6)          9 (24.3)                      
  Negative                       39 (86.7)            35 (77.8)                     29 (78.4)         28 (75.7)                     
  ***NPM1*/n (%)**                                                      0.001^§^                                        0.000^§^    
  Mutation                       7 (15.6)             22 (48.9)                     1 (2.7)           19 (51.4)                     
  Wildtype                       38 (84.4)            23 (51.1)                     36 (97.3)         18 (48.6)                     
  ***CEBPA*/n (%)**                                                     0.557^§^                                        0.305^§^    
  Single mutation                2 (4.4)              1 (2.2)                       4 (10.8)          1 (2.7)                       
  Double mutation                0 (0.0)              0 (0.0)                       2 (5.4)           1 (2.7)                       
  Wild type                      43 (95.6)            44 (97.8)                     31 (83.8)         35 (94.6)                     
  ***DNMT3A*/n (%)**                                                    0.002^§^                                        0.007^§^    
  Mutation                       6 (13.3)             19 (42.2)                     4 (10.8)          14 (37.8)                     
  Wildtype                       39 (86.7)            26 (57.8)                     33 (89.2)         23 (62.2)                     
  ***IDH1*/*IDH2*/n (%)**                                               0.098^§^                                        0.104^§^    
  Mutation                       11 (24.4)            5 (11.1)                      6 (16.2)          12 (32.4)                     
  Wildtype                       34 (75.6)            40 (88.9)                     31 (83.8)         25 (67.6)                     
  ***RUNX1*/n (%)**                                                     1.000^§^                                        1.000^§^    
  Mutation                       4 (8.9)              4 (8.9)                       4 (10.8)          4 (10.8)                      
  Wildtype                       41 (91.1)            41 (91.1)                     33 (89.2)         33 (89.2)                     
  ***MLL-PTD*/n (%)**                                                   1.000^§^                                        0.615^§^    
  Presence                       3 (6.7)              2 (4.4)                       3 (8.1)           1 (2.7)                       
  Absence                        42 (93.3)            43 (95.6)                     34 (91.9)         36 (97.3)                     
  ***NRAS/KRAS*/n (%)**                                                 0.345^§^                                        0.430^§^    
  Mutation                       8 (18.2)             5 (11.1)                      2 (5.4)           5 (13.5)                      
  Wildtype                       36 (81.8)            40 (88.9)                     35 (94.6)         32 (86.5)                     
  ***TET2*/n (%)**                                                      1.000^§^                                        1.000^§^    
  Mutation                       6 (13.3)             6 (13.3)                      2 (5.4)           2 (5.4)                       
  Wildtype                       39 (86.7)            39 (86.7)                     35 (94.6)         35 (94.6)                     
  ***TP53*/n (%)**                                                      0.748^§^                                        1.000^§^    
  Mutation                       6 (13.3)             5 (11.1)                      2 (5.4)           2 (5.4)                       
  Wildtype                       39 (86.7)            40 (88.9)                     35 (94.6)         35 (94.6)                     
  **Relapse/n (%)**                                                     0.078^§^                                        1.000^§^    
  Yes                            12 (26.7)            20 (44.4)                     12 (32.4)         12 (32.4)                     
  No                             33 (73.3)            25 (55.6)                     25 (67.6)         25 (67.6)                     

Abbreviations: WBC, white blood cell; BM, bone marrow; PB, peripheral blood; FAB, French American British. \'\*\' denotes Mann-Whitney U test; \'§\' denotes chi-square test.

###### 

Uni- and multivariate analyses for EFS and OS in chemotherapy-only group

  Variables                            EFS                           OS                         
  ------------------------------------ --------------------- ------- ---- --------------------- -------
  **Univariate analyses**                                                                       
  MiR-98 (high vs. low)                0.516 (0.321-0.829)   0.006        0.522 (0.324-0.841)   0.008
  Age (\< 60 vs. ≥ 60 years)           3.588 (2.005-6.421)   0.000        3.423 (1.919-6.106)   0.000
  WBC (\< 20 vs. ≥ 20×10^9^/L)         1.037 (0.655-1.644)   0.876        1.068 (0.674-1.693)   0.779
  *FLT3-ITD* (positive vs. negative)   1.261 (0.703-2.260)   0.436        1.192 (0.665-2.136)   0.555
  *NPM1* (mutated vs. wild type)       1.120 (0.687-1.827)   0.649        1.044 (0.640-1.704)   0.862
  *DNMT3A* (mutated vs. wild type)     1.407 (0.852-2.322)   0.182        1.432 (0.868-2.362)   0.160
  **Multivariate analyses**                                                                     
  MiR-98 (high vs. low)                1.796 (1.041-3.100)   0.035        1.739 (1.005-3.009)   0.048
  Age (\< 60 vs. ≥ 60 years)           3.681 (2.036-6.657)   0.000        3.411 (1.889-6.158)   0.000
  WBC (\< 20 vs. ≥ 20×10^9^/L)         1.190 (0.721-1.965)   0.496        1.160 (0.703-1.913)   0.562
  *FLT3-ITD* (positive vs. negative)   0.893 (0.491-1.626)   0.712        1.035 (0.565-1.895)   0.913
  *NPM1* (mutated vs. wild type)       1.175 (0.647-2.133)   0.596        1.326 (0.726-2.420)   0.359
  *DNMT3A* (mutated vs. wild type)     0.747 (0.423-1.320)   0.316        0.692 (0.399-1.201)   0.191

Abbreviations: EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; WBC, white blood cell.

###### 

Uni- and multivariate analyses for EFS and OS in allo-HSCT group

  Variables                            EFS                           OS                         
  ------------------------------------ --------------------- ------- ---- --------------------- -------
  **Univariate analyses**                                                                       
  MiR-98 (high vs. low)                1.273 (0.749-2.163)   0.372        1.143 (0.673-1.941)   0.620
  Age (\< 60 vs. ≥ 60 years)           1.042 (0.581-1.868)   0.890        1.448 (0.807-2.599)   0.215
  WBC (\< 20 vs. ≥ 20×10^9^/L)         0.754 (0.442-1.285)   0.299        0.985 (0.578-1.680)   0.956
  *FLT3-ITD* (positive vs. negative)   1.719 (0.915-3.229)   0.092        1.588 (0.848-2.972)   0.148
  *NPM1* (mutated vs. wild type)       0.907 (0.494-1.666)   0.753        0.910 (0.495-1.671)   0.761
  *DNMT3A* (mutated vs. wild type)     1.184 (0.643-2.178)   0.588        1.320 (0.715-2.438)   0.374
  **Multivariate analyses**                                                                     
  MiR-98 (high vs. low)                0.818 (0.437-1.533)   0.531        0.740 (0.392-1.400)   0.355
  Age (\< 60 vs. ≥ 60 years)           1.193 (0.637-2.232)   0.581        1.531 (0.820-2.860)   0.181
  WBC (\< 20 vs. ≥ 20×10^9^/L)         1.372 (0.767-2.454)   0.286        1.075 (0.605-1.907)   0.806
  *FLT3-ITD* (positive vs. negative)   0.529 (0.260-1.075)   0.078        0.559 (0.274-1.139)   0.109
  *NPM1* (mutated vs. wild type)       1.351 (0.630-2.896)   0.439        1.240 (0.579-2.654)   0.580
  *DNMT3A* (mutated vs. wild type)     0.785 (0.410-1.506)   0.467        0.646 (0.333-1.255)   0.197

Abbreviations: EFS, event-free survival; OS, overall survival; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; HR, hazard ratio; CI, confidence interval; WBC, white blood cell.

###### 

Multivariate analyses for EFS and OS based on all patients

  Variables                            EFS                           OS                         
  ------------------------------------ --------------------- ------- ---- --------------------- -------
  MiR-98 (high vs. low)                1.405 (0.945-2.089)   0.093        1.465 (0.979-2.192)   0.064
  Age (\< 60 vs. ≥ 60 years)           2.254 (1.543-3.293)   0.000        2.358 (0.820-2.860)   0.000
  WBC (\< 20 vs. ≥ 20×10^9^/L)         1.349 (0.927-1.963)   0.118        1.177 (0.811-1.709)   0.391
  *FLT3-ITD* (positive vs. negative)   0.781 (0.502-1.215)   0.273        0.886 (0.565-1.389)   0.597
  *NPM1* (mutated v wild type)         1.240 (0.788-1.952)   0.352        1.327 (0.840-2.098)   0.226
  *DNMT3A* (mutated v wild type)       0.731 (0.484-1.103)   0.136        0.685 (0.455-1.031)   0.070
  Chemotherapy vs. allo-HSCT           1.459 (1.015-2.097)   0.041        1.765 (1.219-2.556)   0.003

Abbreviations: EFS, event-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; WBC, white blood cell; Allo-HSCT, allogeneic hematopoietic stem cell transplantation.
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